Does repeat placental growth factor blood sample testing reduce harm from pre-eclampsia to babies?
Not Applicable
Completed
- Conditions
- Pre-eclampsiaPregnancy and Childbirth
- Registration Number
- ISRCTN85912420
- Lead Sponsor
- King's College London
- Brief Summary
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/36056408/ (added 05/09/2022) 2024 Results article in https://doi.org/10.1016/s0140-6736(23)02357-7 (added 12/02/2024) 2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38708607/ (added 07/05/2024)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 1252
Inclusion Criteria
1. Women aged 18 years or more between 22+0 and 35+6 weeks’ gestation with clinical suspicion of pre-eclampsia
2. Viable singleton pregnancy
3. Able to give written informed consent
Exclusion Criteria
Confirmed preterm pre-eclampsia at presentation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Composite of:<br>1. Stillbirth defined as death of a fetus after 24 weeks' gestation and before birth collected by 6 weeks post birth<br>2. Early neonatal death defined as death occurring within the first 7 days of life collected by 6 weeks post birth<br>3. Neonatal unit admission defined as admission of the neonate to the neonatal unit and captured within the first 6 weeks from birth
- Secondary Outcome Measures
Name Time Method